-
Mashup Score: 1
Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7How precise diagnosis of lymphoma offers patients best treatment options - Mayo Clinic Comprehensive Cancer Center Blog - 2 month(s) ago
Dr. Lisa Rimsza discusses how her work as a pathologist helps provide a precise diagnosis so physicians can offer people […]
Source: cancerblog.mayoclinic.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 8
We summarize a presentation of real-world data on tocilizumab for the management of CAR T-cell-associated cytokine release syndrome shared by Delaney at the EBMT-EHA 6th CAR T-cell meeting.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17
Here, we summarize a review published by Cerchietti.1 in Blood on the role of genetic drivers of diffuse large B-cell lymphoma in the lymphoma microenvironment.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Feb 09, 2024 – Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma
Source: www.elicera.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 The Swedish Medical Products Agency has approved the initiation of the phase I/II CARMA study evaluating ELC-301, a CD20-directed CAR T-cell therapy, in patients with B-cell lymphoma who have relapsed. Read more here 👉 https://t.co/243CZXZvmk. #lymphoma #lymsm https://t.co/9ZDN7AF5Y6
-
-
Mashup Score: 9Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL - 4 month(s) ago
Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in…
Source: www.globenewswire.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @US_FDA grants Fast Track designation to NX-5948, a selective BTK degrader, for the treatment of adult patients with R/R CLL/SLL after ≥2 lines of therapy. This follows positive data from the phase I trial. Read more here 👉 https://t.co/SyvLhQa6RU #lymphoma #lymsm https://t.co/OGxRDsxRh7
-
-
Mashup Score: 3Study of Golidocitinib Finds Favorable Efficacy in Pretreated PTCL - 5 month(s) ago
The JAK1 inhibitor golidocitinib led to responses in the challenging disease setting of relapsed/refractory peripheral T-cell lymphoma, as well as manageable hematologic toxicity, in the phase 2 JACKPOT8 study.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
.@michaelwangmd, of @MDAndersonNews, presents primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib + venetoclax vs ibrutinib + placebo in patients with R/R mantle cell #Lymphoma. #lymsm https://t.co/Acly3ypGsn